Organization
Karuna Therapeutics
11 clinical trials
Clinical trial
A Phase 3, Multicenter, Two-part Study With a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) Followed by a 12-week Open-label Extension Part, to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 SchizophreniaStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
An Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaStatus: , Estimated PCD: 2026-02-01
Clinical trial
A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 SchizophreniaStatus: Completed, Estimated PCD: 2022-05-24
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's DiseaseStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's DiseaseStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 SchizophreniaStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 SchizophreniaStatus: Completed, Estimated PCD: 2022-11-29
Clinical trial
A Multi-center, Open-label Study to Assess the Effectiveness, Long-term Safety, Tolerability, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of SchizophreniaStatus: Terminated, Estimated PCD: 2023-03-01
Clinical trial
An Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Subjects With DSM-5 SchizophreniaStatus: Completed, Estimated PCD: 2023-10-03
Clinical trial
A Phase 3 Global, Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's DiseaseStatus: , Estimated PCD: 2026-04-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaStatus: Recruiting, Estimated PCD: 2025-02-01